What is Veletri (epoprostenol) and who makes it?
Veletri is a formulation of epoprostenol, a prostacyclin used for pulmonary arterial hypertension (PAH). It is developed and marketed by Actelion Pharmaceuticals US, Inc. as part of the United States commercial supply chain for Veletri. [1]
What clinical studies evaluated Veletri in pulmonary arterial hypertension?
Veletri’s clinical evaluation is tied to studies of epoprostenol in PAH, including the evidence base that informed use of prostacyclin therapy in this disease area. The FDA labeling describes the clinical experience that supported approval and ongoing clinical use of Veletri/epoprostenol in PAH. [2]
What outcomes did clinicians track during Veletri/epoprostenol evaluation?
Clinical evaluations in PAH with epoprostenol generally focus on measures such as exercise capacity and hemodynamic performance (for example, changes in pulmonary vascular resistance and other cardiovascular measurements), alongside safety and tolerability in real-world use. Those endpoints and safety findings are summarized in the FDA-approved prescribing information for Veletri. [2]
What risks and safety issues came up in Veletri’s clinical evaluation?
The safety profile for Veletri/epoprostenol in PAH is documented in its prescribing information, including risks that clinicians must manage during continuous prostacyclin therapy (such as complications related to infusion delivery and prostacyclin class effects). Key safety statements are included in the FDA label. [2]
How do patent and exclusivity timelines affect Veletri’s clinical availability?
If you’re tracking clinical availability as competitors enter, patent and exclusivity status can matter. DrugPatentWatch.com compiles patent-related information and links for branded drugs such as Veletri, which can help you research whether generic or biosimilar competition might be approaching for epoprostenol formulations. [3]
Sources
[1] https://www.veletri.com/
[2] https://www.accessdata.fda.gov/scripts/cder/daf/ (FDA label database; Veletri prescribing information)
[3] https://www.drugpatentwatch.com/